Inhibition of gastric inhibitory polypeptide signaling prevents obesity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“While GIPR antagonism has been shown to reduce adiposity in preclinical models [64], the clinical data show tirzepatide, a dual GLP-1R/GIPR agonist, produces greater weight loss and glucose lowering than the GLP-1R agonist semaglutide alone [42], particularly at doses which comparably engage the GLP-1R [61].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
In the citing paper
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associate with reduced adiposity [68].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“Obese Lep ob / Lep ob mice exhibit a marked increase in adipose tissue due to hyperphagia caused by mutation of the leptin gen”
BackgroundSerum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Cited by
Items 501–600 of 972
The ‘breakthrough’ obesity drugs that have stunned researchers
Prillaman, M. (2023) · Nature · doi:10.1038/d41586-022-04505-7 · Cited by 22
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
ROSENKILDE, M. M., Lindquist, P., Kizilkaya, H. S., & Gasbjerg, L. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171212 · Cited by 22
“As mentioned above, GIPR activation in humans leads to potentiation of glucose-induced insulin secretion, increases adipose tissue and splanchnic blood flow, and reduces bone resorption [5–14].”
Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 22
Moffett, R. C., Vasu, S., & Flatt, P. R. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.02.006 · Cited by 23
Las hormonas gastrointestinales en el control de la ingesta de alimentos
Álvarez-Crespo, M., González-Matías, L. C., Gil‐Lozano, M., Paz, S. F., Romaní‐Pérez, M., Gago, E. M., & Ferrer, F. M. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)71946-1 · Cited by 30
Role of the Gut on Glucose Homeostasis: Lesson Learned from Metabolic Surgery
Kamvissi, V., Raffaelli, M., Bornstein, S. R., & Mingrone, G. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0642-5 · Cited by 26
Murata, Y., Harada, N., Kishino, S., Iwasaki, K., Ikeguchi, E., Yamane, S., Kato, T., Kanemaru, Y., Sankoda, A., Hatoko, T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102963 · Cited by 26
Molecular Pharmacology of the Incretin Receptors
Al‐Sabah, S. (2015) · Medical Principles and Practice · doi:10.1159/000433437 · Cited by 26
Incretin-Based Therapy and Type 2 Diabetes
Hare, K. J., & Knop, F. K. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00015-1 · Cited by 24
Glucose-dependent insulinotropic polypeptide regulates dipeptide absorption in mouse jejunum
Coon, S. D., Schwartz, J. H., Rajendran, V. M., Jepeal, L. I., & Singh, S. K. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00098.2013 · Cited by 22
“Since GIPR-knockout mice fed a highcalorie diet have been shown not to gain weight (19, 26), a potential target for the treatment of obesity and diabetic symptoms would be to control GIP secretion and/or to modulate GIPR affinity.”
BackgroundSharma, A., Paliwal, G., Upadhyay, N., & Tiwari, A. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0143-4 · Cited by 28
“More-over, the GIPR/genotype attenuates obesity in the ob/ob mouse, possibly because of reduced fat storage and altered lipid metabolism as a direct result of absent GIP receptor (GIPR) action in adipocytes [37].”
BackgroundRetractedReview: Development and therapeutic potential of incretin hormone analogues for type 2 diabetes
Green, B. D., Irwin, N., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050030401 · Cited by 23
Structure-Activity Relationships of Glucose-Dependent Insulinotropic Polypeptide (GIP)
Hinke, S. A., Gelling, R. W., Manhart, S., Lynn, F. C., Pederson, R. A., Kühn‐Wache, K., Rosche, F., Demuth, H., Coy, D. H., & McIntosh, C. H. S. (2003) · Biological Chemistry · doi:10.1515/bc.2003.046 · Cited by 22
“In a recently published report, using GIP receptor null mice, it was demonstrated that chronic removal of GIP action prevented obesity (Miyawaki et al., 2002), fueling interest in development of GIP antagonists.”
BackgroundPhysiological Appetite Regulation and Bariatric Surgery
Ramasamy, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051347 · Cited by 27
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
“320 These observations were confirmed in ob/ob mice and high-fat-fed mice when they were treated with a GIPR antagonist, and also in mice lacking GIP-secreting K cells, confirming the important role of GIP in fat accumulation.”
Han, W., Wang, L., Ohbayashi, K., Takeuchi, M., O’Farrell, L. S., Coşkun, T., Rakhat, Y., Yabe, D., Iwasaki, Y., Seino, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15001 · Cited by 21
Self-citationTakahashi, Y., Fujita, H., Seino, Y., Hattori, S., Hidaka, S., Miyakawa, T., Suzuki, A., Waki, H., Yabe, D., Seino, Y., et al. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13346 · Cited by 23
“6,7 However, it is unclear whether GIP receptor signalling promotes intramuscular fat accumulation as an extra-pancreatic action.”
BackgroundSelf-citationApproved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
Luminal chemosensing in the gastroduodenal mucosa
Kaji, I., & Kaunitz, J. D. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000396 · Cited by 22
Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 24
“Gipr mice exhibit resistance to diet-induced obesity following prolonged high fat feeding (93), associated with”
BackgroundCardiovascular biology of the GIP receptor
Greenwell, A. A., Chahade, J. J., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2019.170228 · Cited by 23
Kanda, J., Furukawa, M., Izumo, N., Shimakura, T., Yamamoto, N., Takahashi, H. E., & Wakabayashi, H. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.03073 · Cited by 21
“GIP directly acts on adipocytes, promotes the uptake of glucose and fatty acids, and induces fat accumulation (22).”
BackgroundMeal test for glucose-dependent insulinotropic peptide (GIP) in obese and type 2 diabetic patients
Škrha, J., Hilgertová, J., Jarolimkova, M., Kunešová, M., & Hill, M. (2010) · Physiological Research · doi:10.33549/physiolres.931893 · Cited by 22
Physiological endocrine control of energy homeostasis and postprandial blood glucose levels.
Gagliardino, J. J. (2005) · PubMed · Cited by 31
New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar, M. (2011) · PubMed · Cited by 29
Gut-Brain Neuropeptides in the Regulation of Ingestive Behaviors and Obesity.
Crowell, M. D., Decker, G. A., Levy, R. L., Jeffrey, R., & Talley, N. J. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00832.x · Cited by 23
“These observations suggest that that inhibition of the GIP signal plays an important role in obesity and obesity-related hyperglycemia”
BackgroundTwincretin as a potential therapeutic for the management of type 2 diabetes with obesity
Usui, R., Yabe, D., & Seino, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13005 · Cited by 20
“to high-fat diet-induced obesity(3), and that chronic activation of GIPR using acylated GIP analog, (d-Ala(2))GIP[Lys(37)PAL], improves glycemia without excess bodyweight gain in high-fat diet-induced obesity in mice(4).”
BackgroundSelf-citationA Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
de Bray, A., Roberts, A. G., Armour, S. L., Tong, J., Huhn, C., Gatin‐Fraudet, B., Roßmann, K., Shilleh, A. H., Jiang, W., Burgos, N. S. F., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01342-6 · Cited by 21
“…has been paid to the GIP axis, as multiple studies showed that either genetic ablation or pharmacological blockade of GIPR protects against body weight gain 6 , and that GIPR agonism has minimal effects on glycemia in patients with type 2 diabetes 7 , potentially owing to GIPR downregulation 8 .”
Efimova, I., Steinberg, I., Zvibel, I., Neumann, A., Mantelmacher, F. D., Drucker, D. J., Fishman, S., & Varol, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643144 · Cited by 22
“In contrast to the overall metabolic protection of mice with stimuli global germline inactivation of the GIPR (14), bone marrow (BM) chimeric mice with immune cell-targeted GIPR-deficiency (Gipr BM) display greater weight gain during HFD feeding, despite similar food intake, concomitantly with increased insulin resist…”
BackgroundPerspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 22
“Miyawaki et al showed protection against diet-induced obesity in GIP receptor knock-out mice [46].”
BackgroundJędrysik, M., Wyszomirski, K., Różańska-Walędziak, A. M., Grosicka-Maciąg, E., Walędziak, M. S., & Chełstowska, B. (2024) · Biomedicines · doi:10.3390/biomedicines12010159 · Cited by 24
“K-cells adipose GIP differ deposition in mice subcutaneous fat cells; it does not affect gastric emptying; and its effect on blood glucose is impaired in chronic hyperglycemia [1,28,29].”
BackgroundScott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 20
“Consistent with this, GIP-receptor knockout mice are resistant to diet-induced obesity (Miyawaki et al., 2002).”
BackgroundEnteroendocrine System and Gut Barrier in Metabolic Disorders
Osinski, C., Moret, D., Clément, K., Serradas, P., & Ribeiro, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073732 · Cited by 22
“The invalidation of the GIP receptor in mice protects these animals from high-fat diet-induced obesity [26].”
BackgroundCurrent knowledge in the neurophysiologic modulation of obesity
Angelopoulos, N., Goula, A., & Tolis, G. (2005) · Metabolism · doi:10.1016/j.metabol.2005.04.005 · Cited by 23
“Wild-type mice fed with a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance [175].”
BackgroundInfluentialOmar, B. A., Banke, E., Guirguis, E., Åkesson, L., Manganiello, V. C., Lyssenko, V., Groop, L., Gomez, M. F., & Degerman, E. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.157 · Cited by 20
de Toro‐Martín, J., Fernández‐Millán, E., Lizárraga-Mollinedo, E., López‐Oliva, M. E., Serradas, P., Escrivá, F., & Álvarez, C. (2014) · Endocrinology · doi:10.1210/en.2013-2043 · Cited by 20
“Differences with other GIP-blockade studies (20, 53), showing reductions in liver fat content despite HFD feeding, may arise from the thrifty catch-up fat programming exhibited by UHF rats (46).”
BackgroundGlucose-dependent insulinotropic polypeptide and its role in obesity
Song, D. H., & Wolfe, M. M. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328011aa88 · Cited by 24
Hira, T., Koga, T., Sasaki, K., & Hara, H. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.031 · Cited by 21
The role of GIPR in food intake control
James-Okoro, P.-P., Lewis, J. E., Gribble, F. M., & Reimann, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532076 · Cited by 23
Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies
Campbell, J. E., & Drucker, D. J. (2025) · Diabetes · doi:10.2337/db25-0393 · Cited by 22
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249239 · Cited by 19
Bariatric surgery: unstressing or boosting the β‐cell?
Mingrone, G., & Castagneto, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01120.x · Cited by 20
Warnakula, S., Hsieh, J., Adeli, K., Hussain, M. M., Tso, P., & Proctor, S. D. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.020 · Cited by 21
Caloric Restriction Paradoxically Increases Adiposity in Mice With Genetically Reduced Insulin
Dionne, D. A., Skovsø, S., Templeman, N. M., Clee, S. M., & Johnson, J. D. (2016) · Endocrinology · doi:10.1210/en.2016-1102 · Cited by 22
Gastrointestinal Hormones and Gut Endocrine Tumors
Vella, A. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00038-1 · Cited by 24
Coleman, D. N., Martín, A., Jin, Y., Lee, K., & Relling, A. E. (2019) · Journal of Animal Science · doi:10.1093/jas/skz154 · Cited by 20
Rational Use of Protein Supplements in the Elderly—Relevance of Gastrointestinal Mechanisms
Chapman, I. M., Oberoi, A., Giezenaar, C., & Soenen, S. (2021) · Nutrients · doi:10.3390/nu13041227 · Cited by 22
“It is not clear what role GIP plays in the control of appetite and feeding, but it may have some effect to stimulate food intake [61].”
BackgroundIs the GLP-1 system a viable therapeutic target for weight reduction?
Tong, J., & Sandoval, D. A. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9170-8 · Cited by 23
“However, the predominant role of GIP seems to be related to increased adipogenesis, likely through direct actions on adipocytes [2], while GLP-1 has been found to be a very important regulator of glucose homeostasis.”
BackgroundWang, S., Liu, J., Li, C., & Wice, B. M. (2004) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540405200106 · Cited by 21
“Recent observations have demonstrated that GIP plays a critical role in promoting high fat diet-induced obesity and insulin resistance (Miyawaki et al. 2002).”
BackgroundCommon variants of GIP are associated with visceral fat accumulation in Japanese adults
Nakayama, K., Watanabe, K., Boonvisut, S., Makishima, S., Miyashita, H., & Iwamoto, S. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00282.2014 · Cited by 20
“GIPR deletion counteracts diet-induced obesity in leptin-deficient mice, and administration of a GIPR antagonist was found to suppress weight gain in mice fed a high-fat diet (10, 15, 34).”
BackgroundMcClean, P. L., Gault, V. A., Irwin, N., McCluskey, J. T., & Flatt, P. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00712.x · Cited by 19
ROSENKILDE, M. M., George, J. T., Véniant, M. M., & Holst, J. J. (2025) · Diabetes · doi:10.2337/dbi24-0027 · Cited by 19
Self-citationProglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Self-citationRegulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“Consistent with this is the observation that the insulinotropic action of GIP is largely dampened in patients with T2D [25 – 31], and that Gipr deficient mice are resistant to diet-induced obesity [32 – 35].”
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
Davies, I., Adriaenssens, A. E., Scott, W. R., Carling, D., Murphy, K. G., MINNION, J. S., Bloom, S. R., Jones, B. J., & Tan, T. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102094 · Cited by 19
Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.009 · Cited by 21
Ghrelin is not suppressed in hyperglycemic clamps by gastric inhibitory polypeptide and arginine
Rudovich, N. N., Dick, D., Moehlig, M., Otto, B., Spranger, J., Rochlitz, H., Ristow, M., Tschoep, M. H., & Pfeiffer, A. F. H. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.10.012 · Cited by 18
Gault, V. A., Hunter, K., Irwin, N., Greer, B., Green, B. D., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2007) · Biological Chemistry · doi:10.1515/bc.2007.019 · Cited by 18
“There was some expectation that GIP antagonists might favour weight loss in the present study, since ablation of GIP signalling was shown to prevent obesity in GIP-R negative mice (Miyawaki et al., 2002).”
BackgroundMartin, T. J. (2007) · Nature Medicine · doi:10.1038/nm0907-1021 · Cited by 18
Kruse, M., Keyhani‐Nejad, F., Isken, F., Nitz, B., Kretschmer, A., Reischl, E., Gala, T. D. L. H., Osterhoff, M. A., Grallert, H., & Pfeiffer, A. F. H. (2015) · Diabetes · doi:10.2337/db15-0478 · Cited by 21
“Genetic ablation of the GIP receptor (GIPR) protects from high-fat diet (HFD)–induced obesity and insulin resistance in mice (5).”
BackgroundResultInfluentialTranscriptional factor Pdx1 is involved in age-related GIP hypersecretion in mice
Ikeguchi, E., Harada, N., Kanemaru, Y., Sankoda, A., Yamane, S., Iwasaki, K., Imajo, M., Murata, Y., Suzuki, K., Joo, E., et al. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00054.2018 · Cited by 18
“In the HFD condition, Rfx6 mRNA expression levels were also increased, and we showed that Rfx6 specifically expressed in K cells played a critical role in differentiation and GIP production of K cells in collaboration with Pdx1.”
BackgroundInfluentialDe Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“It may also mediate the unfavorable consequences, not only of high-fat diets [112], but also of quickly assimilated or high-glycemic-index carbohydrates, a feature of highly processed foods that are commonly found in Western diets [51].”
BackgroundSnook, L. A., Nelson, E. M., Dyck, D. J., Wright, D. C., & Holloway, G. P. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00003.2015 · Cited by 17
“Unfortunately, this model does not exist, and using whole body GIPR knockout or pharmacological approaches to ablate GIP signaling would be confounded by the expected decrease in insulin concentrations (26, 31).”
BackgroundKuwata, H., Okamoto, S., Seino, Y., Murotani, K., Tatsuoka, H., Usui, R., Hamamoto, Y., Kurose, T., Seino, Y., & Yabe, D. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12779 · Cited by 17
Self-citationPetrov, M. S. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1931118 · Cited by 18
“cerol stores, and improved insulin sensitivity [16,23].”
Antibodies in metabolic diseases
Ahrens, B. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.022 · Cited by 20
The incretin system and cardiometabolic disease
Szmitko, P. E., Leiter, L. A., & Verma, S. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70010-6 · Cited by 18
“Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.”
BackgroundInfluentialOkawa, T., Kamiya, H., Himeno, T., Seino, Y., Tsunekawa, S., Hayashi, Y., Harada, N., Yamada, Y., Inagaki, N., Seino, Y., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12129 · Cited by 18
Self-citationIncrétines, sécrétion d’insuline et diabète
Thorens, B. (2003) · médecine/sciences · doi:10.1051/medsci/20031989860 · Cited by 22
Sheng, K., Zhang, H., Yue, J., Gu, W., Gu, C., Zhang, H., & Wu, W. (2018) · Toxicology · doi:10.1016/j.tox.2018.04.007 · Cited by 17
GIP-Based Therapeutics for Diabetes and Obesity
Gault, V. A., Irwin, N., & Flatt, P. R. (2008) · Current Chemical Biology · doi:10.2174/187231308783334108 · Cited by 17
Kubota, M., Yamamoto, K., & Yoshiyama, S. (2023) · Cureus · doi:10.7759/cureus.46490 · Cited by 16
“Regarding effects on body weight, it was reported that at physiological concentrations GIP promotes fat accumulation in a mouse model [16], but at pharmacological concentrations, it suppresses appetite and reduces body weight [17].”
BackgroundGIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
Furber, E. C., Hyatt, K., Collins, K. A. L., Yu, X., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., O’Farrell, L. S., et al. (2023) · Diabetes · doi:10.2337/db23-0172 · Cited by 17
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
Nader, M. A. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-0958-4 · Cited by 18
Role of GIP receptor signaling in β-cell survival
Harada, N., & Inagaki, N. (2017) · Diabetology International · doi:10.1007/s13340-017-0317-z · Cited by 16
Cagiltay, E., Çelik, A., Dixon, J. B., Pouwels, S., Santoro, S., Gupta, A., Ugale, S. M., & Abdul‐Ghani, M. A. (2019) · Diabetic Medicine · doi:10.1111/dme.14191 · Cited by 17
Identification and characterization of adipose surface epitopes
Onogi, Y., Khalil, A., & Ussar, S. (2020) · Biochemical Journal · doi:10.1042/bcj20190462 · Cited by 16
GIP(3-30)NH2 – a tool for the study of GIP physiology
Lynggaard, M. B., Gasbjerg, L. S., Christensen, M., & Knop, F. K. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.011 · Cited by 17
Hormone profiling in a novel enteroendocrine cell line pGIP/neo: STC-1
Hand, K. V., Giblin, L., & Green, B. D. (2012) · Metabolism · doi:10.1016/j.metabol.2012.05.017 · Cited by 16
“[5] Miyawaki K, Yamada Y, Ban N, et al.”
BackgroundShimotoyodome, A., Osaki, N., Onizawa, K., Mizuno, T., Suzukamo, C., Okahara, F., Fukuoka, D., & Hase, T. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00457.2011 · Cited by 16
“Furthermore, the inhibition of GIP signaling has been shown to increase fat oxidation and prevent the onset of obesity induced by a HF diet (19).”
BackgroundFan, Y., Yang, J., Li, X., Zhang, Y., Zheng, H. W., Song, Y., Zhang, N., Shen, C., Fan, X., Ren, F., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85740 · Cited by 18
“The GIP receptor is expressed in adipose tissues,(19) and GIP plays a critical role in accumulation of fat.(20) These observations suggest that GIP had an effect on adipocytes, but there have been no reports published on the relationship between GIP and apelin.”
BackgroundTanaka, K., Miyashiro, I., Yano, M., Kishi, K., Motoori, M., Shingai, T., Noura, S., Ohue, M., Ohigashi, H., & Ishikawa, O. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-146 · Cited by 18
“Furthermore, fat intake induces hypersecretion of GIP, which increases nutrient uptake and triglyceride accumulation in adipocytes [20].”
BackgroundInterplay between bone and incretin hormones: A review
Mabilleau, G. (2016) · Morphologie · doi:10.1016/j.morpho.2016.06.004 · Cited by 18
Canivell, S., Ruano, E. G., Sisó‐Almirall, A., Kostov, B., Paz, L. G., Fernández‐Rebollo, E., Hanzu, F. A., Párrizas, M., Novials, A., & Gomis, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075474 · Cited by 16
“It has been shown that GIPR is involved in obesity and insulin resistance [28].”
BackgroundPoly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“Similarly, GIPR knock-out mice are resistant to diet-induced obesity and protected from insulin resistance [177].”
Intrapancreatic fat deposition and nutritional treatment: the role of various dietary approaches
Pepa, G. D., Salamone, D., Testa, R., Bozzetto, L., & Costabile, G. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad159 · Cited by 17
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
Ciardullo, S., Morieri, M. L., DANIELE, G., Fiorentino, T. V., Mezza, T., Tricò, D., Consoli, A., Prato, S. D., Giorgino, F., Piro, S., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02300-6 · Cited by 18
“Deletion of GIP receptor has been found to counteract high-fat diet induced weight gain in mice, suggesting a causal role of GIP in development of obesity [36].”
BackgroundDouros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Physiology and clinical applications of GIP
Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 16
“Studies using whole-body GIPR KO mice [99], GIP-secretion-deficient mice [100], whole-body administration of GIPR antagonists (see below), and GIP immunoneutralization [101] have shown that fat accumulation and insulin resistance asso‐ ciated with high-fat intake are suppressed by inhibition of GIP…”
Polypeptides synthesized by common bacteria in the human gut improve rodent metabolism
Fan, Y., Lyu, L., Vazquez-Uribe, R., Zhang, W., Bongers, M., Koulouktsis, A., Yang, M., Sereikaité, V., Arora, T., Stankevič, E., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02064-x · Cited by 18
Oviedo-Ojeda, M. F., Roque-Jimenez, J. A., Whalin, M., Lee-Rangel, H. A., & Relling, A. E. (2021) · Journal of Animal Science · doi:10.1093/jas/skab064 · Cited by 15
García‐Jiménez, C. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00014-x · Cited by 15
GIP: No Longer the Neglected Incretin Twin?
Kulkarni, R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001027 · Cited by 16
“Habener, insulinotropin: Glucagon-like peptide i (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.”
BackgroundHron, B. M., Ebbeling, C. B., Feldman, H. A., & Ludwig, D. S. (2017) · Nutrition & Metabolism · doi:10.1186/s12986-017-0198-y · Cited by 16
“Mice lacking GIP receptor are protected against diet-induced obesity, due to higher energy expenditure, and insulin resistance [21].”
BackgroundSurgery for Diabetes: Clinical and Mechanistic Aspects
Kapeluto, J., Tchernof, A., & Biertho, L. D. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.05.008 · Cited by 18
Logical design of oral glucose ingestion pattern minimizing blood glucose in humans
Fujii, M., Murakami, Y., Karasawa, Y., Sumitomo, Y., Fujita, S., Koyama, M., Uda, S., Kubota, H., Inoue, H., Konishi, K., et al. (2019) · npj Systems Biology and Applications · doi:10.1038/s41540-019-0108-1 · Cited by 17
Tharp, W. G., Gupta, D., Sideleva, O., Deacon, C. F., Holst, J. J., Elahi, D., & Pratley, R. E. (2019) · Diabetes · doi:10.2337/db18-1163 · Cited by 16
Self-citationSanches, E. E., Timmermans, M., Topal, B., Çelik, A., Sundbom, M., Ribeiro, R. J. D. S., Parmar, C. D., Ugale, S. M., Proczko, M., Stepaniak, P. S., et al. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1690991 · Cited by 16
“In this mouse models, a decrease in adipocyte mass is seen and resistance to diet-induced obesity [175].”
Background
Metadata
- Authors
- Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., & Seino, Y.
- Affiliations
- Kyoto University (JP)
- University of Copenhagen (DK)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Seino, Yutaka
- Venue
- Nature Medicine
- Published
- 2002-06-17
- Volume
- 8
- Issue
- 7
- Pages
- 738-742
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2102392334
- Cited by
- 963
- References
- 24
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 64 · 2023: 45 · 2022: 38 · 2021: 39 · 2020: 37 · 2019: 66 · 2018: 39 · 2017: 45 · 2016: 38 · 2015: 42 · 2014: 44 · 2013: 38 · 2012: 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, high-fat diet, adiposity, respiratory quotient, fat oxidation, anti-obesity drugs, overnutrition
- MeSH terms
- Adipose Tissue, Animals, Body Weight, Crosses, Genetic, Dietary Fats, Gastric Inhibitory Polypeptide, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.